Ranibizumab for Myopic Neovascularization

Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization

NCT01246089•Instituto de Olhos de Goiania

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Detailed Description

Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months.

Eligibility

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Myopic and CNVM

Exclusion Criteria

•Patients with poor compliance
•* Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients).
•* Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
•* Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
•* Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
•* Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
•* Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.

Locations (1)

Instituto de Olhos de Goiania

Goiânia, Goiás, Brazil

Key Dates

Start Date

July 1, 2009

Primary Completion Date

October 1, 2014

Completion Date

November 1, 2014

Last Updated

January 1, 2014

Enrollment

ACTUAL participants

Conditions

Myopic Choroidal Neovascularization

Interventions

ranibizumab injection

DRUG

Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNV

NCT07402629

Myopic Choroidal Neovascularization

View study

COMPLETED

VEGF and PEDF in Patients With Myopic Choroidal Neovascularization

NCT02175940

Myopic Choroidal NeovascularizationVEGF Aqueous Level+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 1, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions